The round, which was co-led by Pfizer, will support clinical trials of Complexa's kidney disease and pulmonary arterial hypertension treatments.
Pfizer Venture Investments, the corporate venturing arm of pharmaceutical company Pfizer, and venture capital firm New Enterprise Associates (NEA) co-led a $62m series C round for US-based biopharmaceutical firm Complexa on Wednesday.
Banking and asset management firm Edmond de Rothschild Investment Partners and investment firms HBM Healthcare Investments and Jafco also contributed to the round, as did unnamed existing backers.
Founded in 2012, Complexa is working on a therapy called CXA-10 for focal segmental glomerulosclerosis, an orphan disease affecting the…